Hami's Oraxol, novel oral formulation of paclitaxel, inhibits neointimal hyperplasia in rat model

Published: 2004-05-06 06:56:00
Updated: 2004-05-06 06:56:00
Hanmi Pharm said recently that Oraxol, oral formulations of paclitaxol, provide an effective means of inhibiting proliferative response to vascular injury in rat treated at a lower dose (5mg/kg), according to the recent animal experiments.

In the study, which was jointly conducted by a researc...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.